PleoPharma

Funding and NIH signals

• SEC Form D raise Raised $5.5M in debt securities (Form D filed Aug 10, 2026). SEC Form D 0001801323-26-000001 (Aug 10, 2026)
  Evidence (1 event)

  • Aug 10, 2026 · SEC Form D 0001801323-26-000001
    Name of Issuer: PLEOPHARMA, INC.; CIK: 1801323; Address: Phoenixville, PA; Submission type: D; Filing date: 2026-08-10; Industry Group: Pharmaceuticals; Date of First Sale: 2026-07-28; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 5500000; Federal exemptions: 06b
• NIH award NIH awarded $2.2M (NIH grant 1U01DA066079-01, new, notice Aug 12, 2026). NIH RePORTER 1U01DA066079-01 (Aug 12, 2026)
  Evidence (1 event)

  • Aug 12, 2026 · NIH RePORTER 1U01DA066079-01
    Organization: PLEOPHARMA, INC.; City/State: MALVERN, PA; Project number: 1U01DA066079-01; Activity code: U01; Fiscal year: 2026; Award notice date: 2026-08-12; FY total cost (award amount): 2199962; Administering IC: National Institute on Drug Abuse; Project title: Phase 3 Trial of PP-01 for Mitigation of Cannabis Withdrawal in CUD; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

• Raise Series B · $36M · announced Oct 21, 2025 Company release ↗
  Source quote

  • Oct 21, 2025 · Company release ↗
    “PleoPharma, Inc. Closes $36 Million Series B Financing Round”

Raises announced in these releases: $36M disclosed.

From the company’s own releases; this list is partial. All raises and deals